The present study reports an exceedingly rare case of primary squamous cell carcinoma of the liver (PSCCL), a malignancy that has been documented in only ~30 cases worldwide, with both diagnosis and treatment presenting significant challenges. A 72-year-old man presented with right upper abdominal discomfort was admitted to Shaanxi Provincial Cancer Hospital (Xi'an, China). Computed tomography (CT) imaging revealed a space-occupying lesion in the liver. A subsequent percutaneous liver biopsy confirmed a diagnosis of PSCCL. Positron emission tomography/CT was performed to exclude metastasis from other primary sites and confirmed the diagnosis of PSCCL. The patient received combination therapy of envafolimab and albumin-paclitaxel plus cisplatin. Telephone follow-up continued until December 2024 (a total of 18 months), during which the patient achieved and maintained a sustained partial response. The uniqueness of the present case lies in the patient's receipt of an innovative therapeutic regimen combining envafolimab with albumin-paclitaxel and cisplatin, achieving a sustained partial response over an 18-month follow-up period. This outcome not only offers novel insights for the clinical management of PSCCL but also underscores the importance of multidisciplinary comprehensive treatment in rare tumors.

Primary squamous cell carcinoma of the liver (PSCCL) is an extremely rare disease with a poor prognosis. To date, few cancer-related genetic abnormalities in PSCCL have been reported. This report describes a case of PSCCL with FGFR2 alterations in a male patient in his 50s. The patient presented with loss of appetite and epigastric pain. Computed tomography confirmed an irregular mass in the liver and lymphadenopathy in the mediastinum and right supraclavicular region. Biopsies were obtained from the liver and right supraclavicular lymph nodes, and a diagnosis of squamous cell carcinoma was determined. No other primary lesions were identified, and PSCCL was diagnosed. Administration of gemcitabine + cisplatin and gemcitabine + S-1 was discontinued due to allergic reactions. Erdafitinib was then administered; however, the disease progressed. The patient passed away 12 months after the initial treatment. No established treatment options for PSCCL are currently available. Identifying cancer-related genetic abnormalities may help in making treatment decisions.

Primary squamous cell carcinoma of the liver (PSCCL) is a rare intrahepatic primary tumor. Due to a lack of distinctive clinical presentations and radiological features, early diagnosis is challenging. The present study, describes a patient who initially presented with symptoms indicative of cholecystitis but was misdiagnosed with cholangiocarcinoma. It is hypothesized that fluctuations in carcinoembryonic antigen levels during laboratory tests can significantly aid the diagnosis, treatment and prognosis of tumors. Furthermore, imaging studies are essential for the early diagnosis of PSCCL and the exclusion of metastatic squamous cell carcinoma.

Hepatocellular carcinoma is the most common form of primary liver cancer. Intrahepatic cholangiocarcinoma and fibrolamellar carcinoma make up most other cases. The vast majority of intrahepatic cholangiocarcinoma's are adenocarcinoma in nature. Few reports have indicated pure squamous cell or mixed squamous glandular histopathology.

We present the case of a 35-year-old female whose preoperative diagnosis indicated primary keratinizing squamous cell carcinoma (SCC) of the liver. However, histological analysis of surgical resections later confirmed intrahepatic cholangiocarcinoma composed of 95 % squamous and 5 % glandular features.

The change in diagnosis post-operatively is indicative of the pre-operative diagnostic difficulties associated with these newly classified variants. While adenomatous differentiation is the most common form of intrahepatic cholangiocarcinoma, a squamous and mixed histology can be observed.

Surgeons must be aware of new histological variants of cholangiocarcinoma, potential differentials, and direct further research to improve their poor prognosis.

Primary squamous cell carcinoma (SCC) of the liver, a notably uncommon type of cancer, is frequently linked with diverse hepatic conditions including hepatic cysts, hepatolithiasis, and hepatic teratoma. Literature indicates that only approximately 30 cases of primary SCC of the liver have been documented. Herein, we report a 54-year-old previously healthy patient who was presented with cholangitis symptoms. Examinations revealed normal vitals. However, deranged liver function with transaminitis and hyperbilirubinemia were noticed. A CT scan showed a hepatic mass with bile duct dilation. Biopsy confirmed hepatic squamous cell carcinoma, leading to chemotherapy treatment. Despite treatment, the survival outcomes for this cancer remain limited, and the prognosis is generally unfavorable.

Primary squamous cell carcinoma of the liver (SCC) is a rare and challenging pathology. As an aggressive cancer, the prognosis is extremely poor with less than 12 months overall survival. In view of its low prevalence, we report the case of an elderly patient with primary squamous cell carcinoma of the liver.

A 74-year-old female, with no pathological history, presented with acute right hypochondrium pain associated with shivering, asthenia and weight loss. We diagnosed primary hepatic squamous cell carcinoma by pathological analysis.

Primary hepatic squamous cell carcinoma represents a rare malignant tumour with extremely poor prognosis. There is no established treatment protocol for this disease and a multidisciplinary approach is needed to choose the best therapeutic option.

Primary squamous cell carcinoma of the liver (SCC) is extremely rare, making each case report valuable to the medical community. Documentation and analysis of these cases are crucial to enriching knowledge of this rare disease.The absence of established treatment protocols for primary SCC of the liver highlights the need for a multidisciplinary approach to determine the best therapeutic options, which could include innovative treatments and clinical trials.The importance of documenting cases like this can help build a knowledge database. This can help identify trends, improve diagnostic and treatment strategies, and potentially lead to standardized treatment protocols.

Primary hepatic squamous carcinoma is an extremely rare liver tumor type with high malignancy and poor prognosis. We present 18F-FDG PET/CT findings of primary squamous carcinoma of the liver in a 65-year-old man, who was admitted to the hospital with subxiphoid pain in the epigastric region radiating to the left lower back for 2 months. 18F-FDG PET/CT demonstrated a large heterogeneous mild enhancing mass in the left lobe of the liver, with intense circumferential 18F-FDG activity.

Primary hepatic squamous cell carcinoma (SCC) is extremely rare, and only a few dozen cases have been reported to date. It can barely be diagnosed before histopathological examination, which necessitates the exclusion of metastatic tumors. In this case, we present a 60-year-old female patient with no comorbidity. As laboratory tests and imaging examinations were not diagnostic, ultrasonography (US)-guided liver biopsy was performed and eventually revealed a definitive pathological diagnosis of hepatic SCC. After excluding metastasis, the diagnosis of primary hepatic SCC was established, and then chemotherapy and immunotherapy were performed. Additionally, a comprehensive literature search was conducted on primary hepatic SCC using PubMed, Google Scholar, and Web of Science, and a total of 53 articles were retrieved with a time range from 1972 to 2022. A critical analysis was then performed to evaluate previous literature focusing on the clinical characteristics, imaging features, treatments, and prognosis.

Primary squamous cell carcinoma of the liver (PSCCL) is rare. PSCCL's lack of specific clinical manifestations and laboratory tests necessitate preoperative diagnosis via imaging examination. Conventional ultrasound (US) demonstrates a mass with mixed echogenicity, and contrast-enhanced US shows a circular pattern of "fast forward, fast backward or slow backward, high enhancement." Enhanced computed tomography (CT) showed enhancement in the center or edge of the lesion, and the density of the enhanced lesion was lower than that of the liver tissue in the same layer. Positron emission tomography-CT demonstrates an inhomogeneous low-density mass with increased 18F-FDG metabolism. Magnetic resonance imaging shows low signal intensity on T1-weighed images (T1WI) and high signal on T2-weighed images (T2WI). By summarizing the imaging characteristics of PSCCL, this review aims to improve clinicians' understanding of PSCCL and its diagnosis.

Primary squamous cell carcinoma (SCC) of the liver is a rare disease that is difficult to diagnose until the pathology is confirmed. The age of the patients generally ranges from 18 to 83 years. The pathogenesis of primary SCC of the liver remains unclear and therapeutic guidelines have not yet been established. The overall survival rate may be less than 1 year. The prognosis for patients without surgery is worse than that for patients who undergo surgery. Herein, we report a case of primary SCC of the liver that responded well to intravenous carboplatin and 5-flurouracil (5-FU) with the aim of providing an alternative therapeutic option. A 61-year-old woman with no history of alcohol use disorder, cirrhosis, exposure to hepatotoxic chemicals, or a remarkable family history presented to our hospital with a complaint of epigastric pain, poor appetite, and fatigue, which had occurred 3 days before presentation. Blood tests revealed levels of alpha-fetoprotein of <2.0 ng/mL, carcinoembryonic antigen of 4.39 ng/mL, carbohydrate antigen (CA) 19-9 of 1306.15 U/mL, CA 125 of 66.3 U/mL, CA 153 of 19.7 U/mL, and SCC antigen of 8.5 ng/mL. Computed tomography scans of the abdomen showed a 5.8-cm lobulated soft-tissue mass with central necrosis in segment 6 of the liver, which caused compression of the common hepatic duct. Pathological examination of the masses revealed squamous cell carcinoma with focal glandular differentiation. The patient underwent palliative chemotherapy with intravenous carboplatin 150 mg (day 1) and 5-FU 1000 mg (days 1−4) instead of surgery. After two cycles of chemotherapy, jaundice and liver function improved. The patient was discharged in stable condition and was followed up in our outpatient department. Although the patient refused to undergo surgery, no tumor recurrence or distant metastasis was found during the 8-month follow-up period. This report highlights that neoadjuvant chemotherapy with carboplatin and 5-FU can be considered for primary SCC of the liver before a liver resection.

Primary squamous cell carcinoma (SCC) of the liver is an extremely rare disease with a very poor prognosis. An 83-year-old woman was referred to our hospital with left abdominal pain. Laboratory data showed mildly elevated C-reactive protein and biliary enzymes. The tumor markers carcinoembryonic antigen, alpha-fetoprotein, and carbohydrate antigen 19-9 were within normal ranges. Contrast-enhanced computed tomography revealed a 60 mm-sized low-density mass with poor contrast enhancement located in the lateral segment of the liver. The tumor showed low signal on T₁-weighted magnetic resonance imaging (MRI) and high signal on T₂-weighted MRI. The cytology of bile juice showed no malignant findings. Endoscopic ultrasound-guided fine-needle aspiration biopsy was performed, which was suggestive of primary hepatic SCC. Tumor markers cytokeratin 19 fragment (CYFRA) and SCC-related antigen were elevated, at 25.2 ng/mL and 14.7 ng/mL, respectively. Left lobectomy and hilar lymph node dissection were performed. One month after surgery, the tumor marker values showed a marked decrease of 1.8 ng/mL for CYFRA and 0.3 ng/dL for SCC-related antigen. The patient has been without recurrence for more than one and half year postoperatively. SCC-related antigen and CYFRA were markedly decreased after tumor resection in this case, which may suggest their utility as tumor markers for SCC of liver origin.

Primary squamous cell carcinoma (SCC) of the liver is rare and has an extremely poor prognosis. It is very difficult to detect and is sometimes misdiagnosed. It has been reported that male sex, hepatic cyst, hepatolithiasis, hepatic teratoma, and liver cirrhosis may be associated with SCC of the liver. A 67-year-old woman was admitted to our hospital with anorexia, weakness, and right upper quadrant abdominal (RUQ) pain. Sonography and an abdominal computed tomography scan revealed a 36 × 34 cm mass in the liver. Pathological analysis of the sample suggested SCC. According to the negative radiographic findings in other major organs, the tumor was considered primary. The patient was treated with surgical resection and followed by palliative care. Our case died 5 months after the initial presentation.